Enovis (NYSE:ENOV – Get Free Report) had its price objective dropped by stock analysts at Evercore ISI from $62.00 to $58.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Evercore ISI’s price objective suggests a potential upside of 39.02% from the company’s previous close.
A number of other research firms have also weighed in on ENOV. Needham & Company LLC lowered their price objective on shares of Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. dropped their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $68.63.
Check Out Our Latest Report on ENOV
Enovis Stock Performance
Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.03. The business had revenue of $525.20 million during the quarter, compared to the consensus estimate of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The company’s revenue was up 22.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.61 earnings per share. As a group, research analysts forecast that Enovis will post 2.7 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Enovis
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in shares of Enovis by 19.9% during the 1st quarter. GAMMA Investing LLC now owns 1,085 shares of the company’s stock worth $68,000 after purchasing an additional 180 shares during the period. Treasurer of the State of North Carolina boosted its position in shares of Enovis by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 23,252 shares of the company’s stock worth $1,303,000 after buying an additional 220 shares in the last quarter. State of Michigan Retirement System boosted its position in shares of Enovis by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 12,202 shares of the company’s stock worth $762,000 after buying an additional 300 shares in the last quarter. Swiss National Bank boosted its position in shares of Enovis by 0.3% in the 1st quarter. Swiss National Bank now owns 97,000 shares of the company’s stock worth $6,058,000 after buying an additional 300 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its position in shares of Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after buying an additional 371 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Recommended Stories
- Five stocks we like better than Enovis
- What is a Secondary Public Offering? What Investors Need to Know
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Using the MarketBeat Dividend Tax Calculator
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.